25
Participants
Start Date
March 31, 2006
Primary Completion Date
August 31, 2007
Study Completion Date
October 31, 2010
MRKAd5 HIV-1 gag/pol/nef
1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly
MRKAd5 HIV-1 gag/pol/nef placebo
1.0 mL administered intramuscularly
407 Doctors CRS, Surry Hills
Holdsworth House Medical Practice CRS, Darlinghurst
St. Vincent's Hospital CRS, Darlinghurst
Taylor Square Private Clinic CRS, Darlinghurst
407 Doctors (Australia) AIEDRP, Sydney
AIDS Research Initiative (Australia) AIEDRP, Sydney
St. Vincent's Hosp. (Australia) AIEDRP, Sydney
Taylor Square Private Clinic (Australia) AIEDRP, Sydney
Beth Israel Med. Ctr., ACTU, New York
Aaron Diamond AIDS Research Ctr. AIEDRP, New York
Unc Aids Crs, Chapel Hill
UNC, Chapel Hill AIEDRP, Chapel Hill
Duke Univ. Med. Ctr. Adult CRS, Durham
Washington U CRS, St Louis
Univ. of Colorado Health Sciences Ctr. AIEDRP, Denver
Ucsd Aiedrp, San Diego
Ucsf Aiedrp, San Francisco
LA Biomedical Research Institute at Harbor-UCLA AIEDRP, Torrance
Dumc Aiedrp, Durham
AIDS Research Initiative, Darlinghurst CRS, Darlinghurst
Holdsworth House Gen. Practice (Australia) AIEDRP, Sydney
Fenway Community Health Ctr. CRS, Boston
The Miriam Hosp. ACTG CRS, Providence
Acute Infection and Early Disease Research Program
NETWORK
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK
National Institute of Allergy and Infectious Diseases (NIAID)
NIH